Skip to main content
Log in

In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

To investigate the pharmacological properties of mirabegron in in vitro and in vivo, the effects on cAMP accumulation in Chinese hamster ovary (CHO) cells expressing rat β-adrenoceptors, the relaxant activity in isolated rat bladder smooth muscle, and the voiding effects in cerebral infarcted rats were evaluated. Mirabegron increased cAMP accumulation with EC50 value and intrinsic activity of 19 nmol/L and 1.0, respectively, in CHO cells expressing rat β3-adrenoceptors. The EC50 values and the intrinsic activities of mirabegron were 610 nmol/L and 0.6 for rat β1-adrenoceptors and were sumless and 0.1 for β2-adrenoceptors, respectively. Mirabegron showed concentration-dependent relaxant and full agonistic effects in rat bladder strips under passive tension with EC50 value of 290 nmol/L. The concentration–response curve of mirabegron was affected neither by the β1-adrenoceptor selective antagonist CGP-20712A nor by the β2-adrenoceptor selective antagonist ICI-118,551. In in vivo studies with cerebral infarcted rats, a significant decrease in the volume voided per micturition compared with sham-operated rats was observed. Mirabegron dose-dependently increased the volume voided per micturition. In conclusion, we have extended the selectivity profile of mirabegron to rats and demonstrated that it is effective via stimulation of β3-adrenoceptors in a rat cerebral infarction model of detrusor overactivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Kerrebroeck PV, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178

    Article  PubMed  Google Scholar 

  • Andersson K-E, Arner A (2004) Urinary bladder contraction and relaxation physiology and pathophysiology. Physiol Rev 84:935–986

    Article  PubMed  CAS  Google Scholar 

  • Athanasopoulos A, Giannitsas K (2011) An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol 816342

  • Chapple C, Wyndaele JJ, Van Kerrebroeck P, Radziszewski P, Dvorak V, Boerrigter P (2010) Dose-ranging study of once-daily mirabegron (YM-178) a novel selective β3-adrenoceptor agonist in patients with overactive bladder (OAB). Eur Urol Suppl 9:249

    Article  Google Scholar 

  • de Groat WC, Yoshimura N (2001) Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 41:691–721

    Article  PubMed  Google Scholar 

  • Dolan JA, Muenkel HA, Burns MG, Pellegrino SM, Fraser CM, Pietri F, Strosberg AD, Largis EE, Dutia MD, Bloom JD (1994) β3 Adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther 269:1000–1006

    PubMed  CAS  Google Scholar 

  • Fujimura T, Tamura K, Tsutsumi T, Yamamoto T, Nakamura K, Koibuchi Y, Kobayayashi M, Yamaguchi O (1999) Expression and possible functional role of the β3-adrenoceptor in human and rat detrusor muscle. J Urol 161:680–685

    Article  PubMed  CAS  Google Scholar 

  • Griffiths DJ, McCracken PN, Harrison GM, Gormley EA, Moore K, Hooper R, McEwan AJB, Triscott J (1994) Cerebral aetiology of urinary urge incontinence in elderly people. Age Ageing 23:246–250

    Article  PubMed  CAS  Google Scholar 

  • Hegde SS, Mammen M, Jasper JR (2004) Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Investig Drugs 5:40–44

    PubMed  CAS  Google Scholar 

  • Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson K-E (1999) Functional and molecular biological evidence for a possible β3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126:819–825

    Article  PubMed  CAS  Google Scholar 

  • Igawa Y, Aizawa N, Homma Y (2010) Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol 51(12):811–818

    Article  PubMed  Google Scholar 

  • Ishiura Y (1996) Experimental study of voiding dysfunction induced by cerebral infarction in rats. Jpn J Urol 87:1221–1230

    CAS  Google Scholar 

  • Kaidoh K, Igawa Y, Takeda H, Yamazaki Y, Akahane S, Miyata H, Ajisawa Y, Nishizawa O, Andersson K-E (2002) Effects of selective β2 and β3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 168:1247–1252

    Article  PubMed  CAS  Google Scholar 

  • Khan Z, Starer P, Yang WC, Bhola A (1990) Analysis of voiding disorders in patients with cerebrovascular accidents. Urology 35:265–270

    Article  PubMed  CAS  Google Scholar 

  • Khullar V, Cambronero J, Stroberg P, Angulo J, Boerrigter P, Blauwet MB, Wooning M (2011) The efficacy and tolerability of mirabegron in patients with overactive bladder—results from a European-Australian Phase III trial. Eur Urol Suppl 10:278–279

    Article  Google Scholar 

  • Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, Lipton RB, Diokno AC (2001) Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community based survey. Urology 57:1044–1050

    Article  PubMed  CAS  Google Scholar 

  • Liggett SB (1992) Functional properties of the rat and human β3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol 42:634–637

    PubMed  CAS  Google Scholar 

  • Longa EZ, Weinstein PR, Carlson S, Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84–91

    Article  PubMed  CAS  Google Scholar 

  • Madersbacher H, Halaska M, Voigt R, Höfner K (1999) A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84:646–651

    Article  PubMed  CAS  Google Scholar 

  • Michel MC, Sand C (2009) Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder. World J Urol 27:711–715

    Article  PubMed  CAS  Google Scholar 

  • Michel MC, Ochodnicky P, Homma Y, Igawa Y (2011) β-Adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther 131:40–49

    Article  PubMed  CAS  Google Scholar 

  • Nakada Y, Yokoyama O, Komatsu K, Kodama K, Yotsuyanagi S, Niikura S, Nagasaka Y, Namiki M (2000) Effects of aniracetam on bladder overactivity in rats with cerebral infarction. J Pharmacol Exp Ther 293:921–928

    PubMed  CAS  Google Scholar 

  • Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N (2011) The efficacy and safety of mirabegron in patients with overactive bladder syndrome—results from a North-American Phase III trial. Eur Urol Suppl 10:278

    Article  Google Scholar 

  • Pehrson R, Stenman E, Andersson K-E (2003) Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction. Eur Urol 44:495–499

    Article  PubMed  CAS  Google Scholar 

  • Suzuki M, Ohtake A, Yoshino T, Yuyama H, Hayashi A, Ukai M, Okutsu H, Noguchi Y, Sato S, Sasamata M (2005) Effect of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. Eur J Pharmacol 512:61–66

    Article  PubMed  CAS  Google Scholar 

  • Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O (2007) Effect of (R)-2-(2-Aminothiazol-4-yl)-4-{2-[(2-hydroxy-2- phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642–647

    Article  PubMed  CAS  Google Scholar 

  • Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S (1999) Evidence for β3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 288:1367–1373

    PubMed  CAS  Google Scholar 

  • Tsuchida S, Noto H, Yamaguchi O, Itoh M (1983) Urodynamic studies on hemiplegic patients after cerebrovascular accident. Urology 21:315–318

    Article  PubMed  CAS  Google Scholar 

  • Uchida H, Shishido H, Nomiya M, Yamaguchi O (2005) Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via β-adrenoceptors. Eur J Pharmacol 518:195–202

    Article  PubMed  CAS  Google Scholar 

  • Wagg A, Compion G, Fahey A, Siddiqui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. doi:10.1111/j.1464-410X.2012.11023.x

  • Yamaguchi O (2002) β3-adrenoceptors in human detrusor muscle. Urology 59(Suppl 5A):25–29

    Article  PubMed  Google Scholar 

  • Yamazaki Y, Takeda H, Akahane M, Igawa Y, Nishizawa O, Ajisawa Y (1998) Species differences in the distribution of β-adrenoceptor subtypes in bladder smooth muscle. Br J Pharmacol 124:593–599

    Article  PubMed  CAS  Google Scholar 

  • Yokoyama O, Yoshiyama M, Namik M, de Groat WC (1999) Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Am J Physiol Regul Integr Comp Physiol 276:935–942

    Google Scholar 

  • Yokoyama O, Yoshiyama M, Namiki M, de Groat MC (2002) Changes in dopaminergic and glutamatergic excitatory mechanisms of micturition reflex after middle cerebral artery occlusion in conscious rats. Exp Neurol 173:129–135

    Google Scholar 

Download references

Acknowledgments

The authors are grateful to Dr. Cees Korstanje (Astellas Pharma Europe B.V.) for helpful comments and suggestions.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Toshiki Hatanaka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hatanaka, T., Ukai, M., Watanabe, M. et al. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. Naunyn-Schmiedeberg's Arch Pharmacol 386, 247–253 (2013). https://doi.org/10.1007/s00210-012-0821-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-012-0821-4

Keywords

Navigation